Skip directly to page options Skip directly to A-Z link
Volume 20, Number 3—March 2014
Research

Comparison of Imported Plasmodium ovale curtisi and P. ovale wallikeri Infections among Patients in Spain, 2005–2011

Gerardo Rojo-MarcosComments to Author , José Miguel Rubio-Muñoz, Germán Ramírez-Olivencia, Silvia García-Bujalance, Rosa Elcuaz-Romano, Marta Díaz-Menéndez, María Calderón, Isabel García-Bermejo, José Manuel Ruiz-Giardín, Francisco Jesús Merino-Fernández, Diego Torrús-Tendero, Alberto Delgado-Iribarren, Mónica Ribell-Bachs, Juan Arévalo-Serrano, and Juan Cuadros-González
Author affiliations: Príncipe de Asturias University Hospital, Madrid, Spain (G. Rojo-Marcos, J. Arévalo-Serrano, J. Cuadros-González,); Instituto de Salud Carlos III, Madrid (J.M. Rubio-Muñoz); Carlos III Hospital, Madrid (G. Ramírez-Olivencia); La Paz University Hospital, Madrid (S García-Bujalance); Doctor Negrín University Hospital, Las Palmas de Gran Canaria, Spain (R. Elcuaz-Romano); Ramón y Cajal Hospital, Madrid (M. Díaz-Menéndez); Gregorio Marañón University Hospital, Madrid (M. Calderón); Getafe University Hospital, Madrid (I. García-Bermejo); University Hospital of Fuenlabrada, Madrid (J. M. Ruiz-Giardín); Severo Ochoa University Hospital, Madrid (F.J. Merino-Fernández); University General Hospital of Alicante, Alicante, Spain (D. Torrús-Tendero); University Hospital Fundación Alcorcón, Madrid (A. Delgado-Iribarren); Hospital General de Granollers, Barcelona, Spain (M. Ribell-Bachs).

Main Article

Table 3

Clinical and therapeutic characteristics of patients with imported Plasmodium ovale curtisi or Povale wallikeri infections, Spain, 2005–2011*

Characteristic P. ovale curtisi, n = 21 P. ovale wallikeri, n = 14 p value
Asymptomatic 3 (14.3) 0 0.259
Fever 18 (85.7) 14 (100.0) 0.259
Tertian fever 1 (4.8) 3 (21.4) 0.279
Maximum temperature, ºC, median (IQR) 38.4 (37.5–40.0) 39.7 (38.9–40.5) 0.088
Chills 3 (14.3) 3 (21.4) 0.664
Sweating 0 1 (7.1) 0.400
Headache 6 (28.6) 4 (28.6) >0.999
Nauseas 0 3 (21.4) 0.056
Vomitus 0 3 (21.4) 0.056
Astenia 2 (9.5) 3 (21.4) 0.369
Epigastralgia 2 (9.5) 0 0.506
Arthralgia 5 (23.8) 3 (21.4) >0.999
Myalgia 6 (28.6) 4 (28.6) >0.999
Diarrhea 1 (4.8) 1 (7.1) >0.999
Chest pain 1 (4.8) 1 (7.1) >0.999
Cough 4 (19.0) 3 (21.4) >0.999
Dyspnea 0 1 (7.1) 0.400
Dizziness 2 (9.5) 0 >0.999
Splenomegaly
 5 (23.8)
 3 (21.4)
 >0.999
Complications or severe malaria 2 (9.5) 2 (14.3) >0.999
Hemolytic crisis 1 (4.8) 0
Severe anemia, hemoglobin <7 g/dL 1 (4.8) 1 (7.1)
Acute respiratory distress syndrome
 0
 1 (7.1)
Admission to hospital 13 (61.9) 13 (92.9) 0.056
Duration of hospitalization, d, median (IQR)
 4 (3.0–7.5)
 5 (3.5–7.5)
 0.390
Treatment 0.563
Chloroquine 12 (57.1) 7 (50.0)
Other treatment 8 (38.1) 7 (50.0)
Quinine + doxycycline 3 (14.3) 4 (28.6)
Atovaquone/proguanil 3 (14.3) 1 (7.1)
Quinine + clindamycin + chloroquine/proguanil 1 (4.8) 0
Quinine + clindamycin + chloroquine 0 1 (7.1)
Mefloquine 0 1 (7.1)
Atovaquone/proguanil + chloroquine 1 (4.8) 0
No treatment 1 (4.8) 0
Primaquine
 14 (66.7)
 10 (71.4)
 >0.999
Compliance 19/21 (90.5) 13/13 (100.0)† 0.513

*Values are no. (%) patients or no. positive/total no. (%) patients unless otherwise indicated. IQR, interquartile range.
†One patient was lost to follow-up.

Main Article

Page created: February 19, 2014
Page updated: February 19, 2014
Page reviewed: February 19, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external